UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 3.164

Sortiert nach

A Case of Delayed Recovery From Ketosis in a Patient With Diabetic Ketoacidosis Following the Treatment With Empagliflozin

Journal of the Japan Diabetes Society, 2016/04/30, Vol.59(4), pp.196-202

2016

Volltextzugriff (PDF)

Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial

Journal of the American College of Cardiology, 2021-03, Vol.77 (11), p.1381-1392

2021

Volltextzugriff (PDF)

Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT‐2 study): 52‐week results from a randomized controlled trial

Diabetes, obesity & metabolism, 2020-09, Vol.22 (9), p.1516-1526

2020

Volltextzugriff (PDF)

Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption

International journal of molecular sciences, 2023-03, Vol.24 (7), p.6278

2023

Volltextzugriff (PDF)

Early initiation of sodium-glucose cotransporter 2 inhibitors in patients undergoing cardiac surgery: Are we ready for prime time?

International journal of cardiology, 2024-11, Vol.414, p.132430, Article 132430

2024

Volltextzugriff (PDF)

Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials

Diabetes, obesity & metabolism, 2020-09, Vol.22 (9), p.1619-1627

2020

Volltextzugriff (PDF)

Combination Therapy Using Pemafibrate and Dapagliflozin for Metabolic Dysfunction-associated Fatty Liver Disease

Internal Medicine, 2023, pp.0277-22

2023

Volltextzugriff (PDF)

The Na+‐coupled glucose transporter SGLT2 interacts with its accessory unit MAP17 in vitro and their expressions overlap in the renal proximal tubule

FEBS letters, 2018-10, Vol.592 (19), p.3317-3326

2018

Volltextzugriff (PDF)

The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure

Diabetologia, 2018-10, Vol.61 (10), p.2098-2107

2018

Volltextzugriff (PDF)

Az SGLT2-gátlók lehetséges hatásai a kardiovaszkuláris megbetegedésekben

Cardiologia Hungarica (Budapest), 2023-09, Vol.53 (4), p.360-364

Kosztin, Annamária

2023

Volltextzugriff (PDF)

Cover Feature: Diarylcuprates for Selective Syntheses of Multifunctionalized Ketones from Thioesters under Mild Conditions (Chem. Eur. J. 26/2022)

Chemistry : a European journal, 2022-05, Vol.28 (26), p.n/a

2022

Volltextzugriff (PDF)

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee

Journal of the American College of Cardiology, 2021-02, Vol.77 (6), p.772-810

2021

Volltextzugriff (PDF)

Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics

American journal of kidney diseases, 2021-02, Vol.77 (2), p.280-286

Packer, Milton

2021

Volltextzugriff (PDF)

An Overview of the Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Hematological Parameters in Diabetic Patients

المجلة العراقية للصيدلة, 2023-06, Vol.20 (1), p.65-71

2023

Volltextzugriff (PDF)

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

American journal of kidney diseases, 2021-01, Vol.77 (1), p.94-109

2021

Volltextzugriff (PDF)

Empagliflozin protects heart from inflammation and energy depletion via AMPK activation

Pharmacological research, 2020-08, Vol.158, p.104870-104870, Article 104870

2020

Volltextzugriff (PDF)

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

Diabetes, obesity & metabolism, 2011-07, Vol.13 (7), p.669-672

2011

Volltextzugriff (PDF)

Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors

Journal of the American College of Cardiology, 2024-04, Vol.83 (16), p.1568-1578

2024

Volltextzugriff (PDF)

Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition

Cellular signalling, 2020-04, Vol.68 (C), p.109506-109506, Article 109506

2020

Volltextzugriff (PDF)

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial

Circulation (New York, N.Y.), 2019-11, Vol.140 (21), p.1693-1702

2019

Volltextzugriff (PDF)

Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022

American journal of kidney diseases, 2022-05, Vol.79 (5), p.728-736

2022

Volltextzugriff (PDF)

Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan

Circulation Journal, 2022/09/06, pp.CJ-22-0086

2022

Volltextzugriff (PDF)

Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-Controlled Study

Clinical therapeutics, 2024-07

2024

Volltextzugriff (PDF)

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Journal of the American College of Cardiology, 2020-09, Vol.76 (9), p.1117-1145

2020

Volltextzugriff (PDF)

SGLT2 inhibitors: A groundbreaking class of cardiovascular drugs, but who benefits most?

International journal of cardiology, 2024-10, Vol.412, p.132326, Article 132326

2024

Volltextzugriff (PDF)

1 – 25 von 3.164

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.517)
Mit Volltextzugriff
(2.855)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.595)
Life Sciences & Biomedicine
(2.549)
Diabetes
(1.382)
Humans
(1.310)
Sglt2 Inhibitor
(1.142)
Sglt2 Inhibitors
(1.100)
Endocrinology & Metabolism
(947)
Diabetes Mellitus
(881)
Diabetes Mellitus, Type 2 - Drug Therapy
(860)
Glucose
(814)
Type 2 Diabetes
(804)
Heart Failure
(651)
Male
(520)
Pharmacology & Pharmacy
(505)
Cardiovascular System & Cardiology
(493)
Sglt2
(485)
Cardiac & Cardiovascular Systems
(454)
Dapagliflozin
(442)
Hypoglycemic Agents - Therapeutic Use
(436)
Female
(408)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(71)
... seit 30 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

A Case of Delayed Recovery From Ketosis in a Patient With Diabetic Ketoacidosis Following the Treatment With Empagliflozin

Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial

Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT‐2 study): 52‐week results from a randomized controlled trial

Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption

Early initiation of sodium-glucose cotransporter 2 inhibitors in patients undergoing cardiac surgery: Are we ready for prime time?

Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials

Combination Therapy Using Pemafibrate and Dapagliflozin for Metabolic Dysfunction-associated Fatty Liver Disease

The Na+‐coupled glucose transporter SGLT2 interacts with its accessory unit MAP17 in vitro and their expressions overlap in the renal proximal tubule

The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure

Az SGLT2-gátlók lehetséges hatásai a kardiovaszkuláris megbetegedésekben

Cover Feature: Diarylcuprates for Selective Syntheses of Multifunctionalized Ketones from Thioesters under Mild Conditions (Chem. Eur. J. 26/2022)

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee

Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics

An Overview of the Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Hematological Parameters in Diabetic Patients

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Empagliflozin protects heart from inflammation and energy depletion via AMPK activation

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors

Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial

Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022

Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan

Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-Controlled Study

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

SGLT2 inhibitors: A groundbreaking class of cardiovascular drugs, but who benefits most?

Suchergebnisse filtern